Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 9, Pages 1967
Publisher
MDPI AG
Online
2017-09-14
DOI
10.3390/ijms18091967
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
- (2017) Robert L Coleman et al. LANCET ONCOLOGY
- Targeting the tumour microenvironment in ovarian cancer
- (2016) Jean M. Hansen et al. EUROPEAN JOURNAL OF CANCER
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Angiopoietins Promote Ovarian Cancer Progression by Establishing a Procancer Microenvironment
- (2014) Melissa K. Brunckhorst et al. AMERICAN JOURNAL OF PATHOLOGY
- PDGF receptor signaling networks in normal and cancer cells
- (2014) Jean-Baptiste Demoulin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- The emerging role of anti-angiogenic therapy in ovarian cancer
- (2014) VINCENZA CONTEDUCA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
- (2014) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- TGF- Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment
- (2013) T.-L. Yeung et al. CANCER RESEARCH
- Morbidity of Surgery After Neoadjuvant Chemotherapy Including Bevacizumab for Advanced Ovarian Cancer
- (2013) Elisabeth Chéreau et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
- (2013) Nikos Gavalas et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment
- (2013) Takamitsu Sasaki et al. Biomed Research International
- Role of angiogenesis in the pathogenesis of cancer
- (2012) Paulo M. Hoff et al. CANCER TREATMENT REVIEWS
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- BMP-2 signaling in ovarian cancer and its association with poor prognosis
- (2009) Cécile Le Page et al. Journal of Ovarian Research
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started